358 related articles for article (PubMed ID: 28089741)
1. Inflammatory myopathy in a patient with Aicardi-Goutières syndrome.
Tumienė B; Voisin N; Preikšaitienė E; Petroška D; Grikinienė J; Samaitienė R; Utkus A; Reymond A; Kučinskas V
Eur J Med Genet; 2017 Mar; 60(3):154-158. PubMed ID: 28089741
[TBL] [Abstract][Full Text] [Related]
2. Dysregulation of the immune system in Aicardi-Goutières syndrome: another example in a TREX1-mutated patient.
Olivieri I; Cattalini M; Tonduti D; La Piana R; Uggetti C; Galli J; Meini A; Tincani A; Moratto D; Fazzi E; Balottin U; Orcesi S
Lupus; 2013 Sep; 22(10):1064-9. PubMed ID: 23918923
[TBL] [Abstract][Full Text] [Related]
3. Assessment of interferon-related biomarkers in Aicardi-Goutières syndrome associated with mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, and ADAR: a case-control study.
Rice GI; Forte GM; Szynkiewicz M; Chase DS; Aeby A; Abdel-Hamid MS; Ackroyd S; Allcock R; Bailey KM; Balottin U; Barnerias C; Bernard G; Bodemer C; Botella MP; Cereda C; Chandler KE; Dabydeen L; Dale RC; De Laet C; De Goede CG; Del Toro M; Effat L; Enamorado NN; Fazzi E; Gener B; Haldre M; Lin JP; Livingston JH; Lourenco CM; Marques W; Oades P; Peterson P; Rasmussen M; Roubertie A; Schmidt JL; Shalev SA; Simon R; Spiegel R; Swoboda KJ; Temtamy SA; Vassallo G; Vilain CN; Vogt J; Wermenbol V; Whitehouse WP; Soler D; Olivieri I; Orcesi S; Aglan MS; Zaki MS; Abdel-Salam GM; Vanderver A; Kisand K; Rozenberg F; Lebon P; Crow YJ
Lancet Neurol; 2013 Dec; 12(12):1159-69. PubMed ID: 24183309
[TBL] [Abstract][Full Text] [Related]
4. Aicardi-Goutières syndrome.
Crow YJ
Handb Clin Neurol; 2013; 113():1629-35. PubMed ID: 23622384
[TBL] [Abstract][Full Text] [Related]
5. Generation of three iPSC lines from fibroblasts of a patient with Aicardi Goutières Syndrome mutated in TREX1.
Ferraro RM; Lanzi G; Masneri S; Barisani C; Piovani G; Savio G; Cattalini M; Galli J; Cereda C; Muzi-Falconi M; Orcesi S; Fazzi E; Giliani S
Stem Cell Res; 2019 Dec; 41():101580. PubMed ID: 31644995
[TBL] [Abstract][Full Text] [Related]
6. A nationwide survey of Aicardi-Goutières syndrome patients identifies a strong association between dominant TREX1 mutations and chilblain lesions: Japanese cohort study.
Abe J; Nakamura K; Nishikomori R; Kato M; Mitsuiki N; Izawa K; Awaya T; Kawai T; Yasumi T; Toyoshima I; Hasegawa K; Ohshima Y; Hiragi T; Sasahara Y; Suzuki Y; Kikuchi M; Osaka H; Ohya T; Ninomiya S; Fujikawa S; Akasaka M; Iwata N; Kawakita A; Funatsuka M; Shintaku H; Ohara O; Ichinose H; Heike T
Rheumatology (Oxford); 2014 Mar; 53(3):448-58. PubMed ID: 24300241
[TBL] [Abstract][Full Text] [Related]
7. Aicardi-Goutières syndrome with muscle involvement in early infancy.
Deigendesch N; Morales-Gonzalez S; Weschke B; Goebel HH; Schuelke M; Stenzel W
Neuropathol Appl Neurobiol; 2018 Dec; 44(7):737-742. PubMed ID: 29210089
[No Abstract] [Full Text] [Related]
8. Aicardi-Goutières syndrome protein TREX1 suppresses L1 and maintains genome integrity through exonuclease-independent ORF1p depletion.
Li P; Du J; Goodier JL; Hou J; Kang J; Kazazian HH; Zhao K; Yu XF
Nucleic Acids Res; 2017 May; 45(8):4619-4631. PubMed ID: 28334850
[TBL] [Abstract][Full Text] [Related]
9. Expanding the phenotypic spectrum of lupus erythematosus in Aicardi-Goutières syndrome.
Ramantani G; Kohlhase J; Hertzberg C; Innes AM; Engel K; Hunger S; Borozdin W; Mah JK; Ungerath K; Walkenhorst H; Richardt HH; Buckard J; Bevot A; Siegel C; von Stülpnagel C; Ikonomidou C; Thomas K; Proud V; Niemann F; Wieczorek D; Häusler M; Niggemann P; Baltaci V; Conrad K; Lebon P; Lee-Kirsch MA
Arthritis Rheum; 2010 May; 62(5):1469-77. PubMed ID: 20131292
[TBL] [Abstract][Full Text] [Related]
10. Therapies in Aicardi-Goutières syndrome.
Crow YJ; Vanderver A; Orcesi S; Kuijpers TW; Rice GI
Clin Exp Immunol; 2014 Jan; 175(1):1-8. PubMed ID: 23607857
[TBL] [Abstract][Full Text] [Related]
11. Different mutations in three prime repair exonuclease 1 and ribonuclease H2 genes affect clinical features in Aicardi-Goutieres syndrome.
Izzotti A; Longobardi M; Cartiglia C; Anzuini F; Arrigo P; Fazzi E; Orcesi S; Piana RL; Pulliero A
J Child Neurol; 2012 Jan; 27(1):51-60. PubMed ID: 21862834
[TBL] [Abstract][Full Text] [Related]
12. Intracerebral large artery disease in Aicardi-Goutières syndrome with TREX1 mutation: a case report.
Wu CC; Peng SS; Lee WT
Neurol Sci; 2020 Nov; 41(11):3353-3356. PubMed ID: 32524323
[TBL] [Abstract][Full Text] [Related]
13. Phenotypic variability of a TREX1 variant in Aicardi-Goutieres type 1 patients from the Indian subcontinent.
Abraham SSC; Yoganathan S; Koshy B; Oommen SP; Simon A; Mathai S; Korula S; Mathew L; Sathishkumar D; Jasper A; George R; Danda S
Eur J Med Genet; 2021 Sep; 64(9):104291. PubMed ID: 34303877
[TBL] [Abstract][Full Text] [Related]
14. Phenotypic variation in Aicardi-Goutières syndrome explained by cell-specific IFN-stimulated gene response and cytokine release.
Cuadrado E; Michailidou I; van Bodegraven EJ; Jansen MH; Sluijs JA; Geerts D; Couraud PO; De Filippis L; Vescovi AL; Kuijpers TW; Hol EM
J Immunol; 2015 Apr; 194(8):3623-33. PubMed ID: 25769924
[TBL] [Abstract][Full Text] [Related]
15. Aicardi-Goutières syndrome (AGS).
Stephenson JB
Eur J Paediatr Neurol; 2008 Sep; 12(5):355-8. PubMed ID: 18343173
[TBL] [Abstract][Full Text] [Related]
16. Neonatal detection of Aicardi Goutières Syndrome by increased C26:0 lysophosphatidylcholine and interferon signature on newborn screening blood spots.
Armangue T; Orsini JJ; Takanohashi A; Gavazzi F; Conant A; Ulrick N; Morrissey MA; Nahhas N; Helman G; Gordish-Dressman H; Orcesi S; Tonduti D; Stutterd C; van Haren K; Toro C; Iglesias AD; van der Knaap MS; Goldbach Mansky R; Moser AB; Jones RO; Vanderver A
Mol Genet Metab; 2017 Nov; 122(3):134-139. PubMed ID: 28739201
[TBL] [Abstract][Full Text] [Related]
17. Systematic analysis of genotype-phenotype variability in siblings with Aicardi Goutières Syndrome (AGS).
de Barcelos IP; Woidill S; Gavazzi F; Modesti NB; Sevagamoorthy A; Vanderver A; Adang L
Mol Genet Metab; 2024 May; 142(1):108346. PubMed ID: 38368708
[TBL] [Abstract][Full Text] [Related]
18. Aicardi-Goutières syndrome: A monogenic type I interferonopathy.
Liu A; Ying S
Scand J Immunol; 2023 Oct; 98(4):e13314. PubMed ID: 37515439
[TBL] [Abstract][Full Text] [Related]
19. Heterozygous TREX1 p.Asp18Asn mutation can cause variable neurological symptoms in a family with Aicardi-Goutieres syndrome/familial chilblain lupus.
Abe J; Izawa K; Nishikomori R; Awaya T; Kawai T; Yasumi T; Hiragi N; Hiragi T; Ohshima Y; Heike T
Rheumatology (Oxford); 2013 Feb; 52(2):406-8. PubMed ID: 22829693
[No Abstract] [Full Text] [Related]
20. Inherited or de novo mutation affecting aspartate 18 of TREX1 results in either familial chilblain lupus or Aicardi-Goutières syndrome.
Tüngler V; Silver RM; Walkenhorst H; Günther C; Lee-Kirsch MA
Br J Dermatol; 2012 Jul; 167(1):212-4. PubMed ID: 22356656
[No Abstract] [Full Text] [Related]
[Next] [New Search]
